GNC 077
Alternative Names: GNC-077Latest Information Update: 16 Mar 2025
At a glance
- Originator Sichuan Baili Pharmaceutical
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 01 Jan 2025 Sichuan Baili Pharmaceutical plans a phase I trial for Gastrointestinal-cancer along with Solid tumour (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China in January 2025 (IV) (NCT06755242)
- 30 Oct 2024 Phase-I clinical trials in Breast cancer (Late-stage disease, Metastatic disease) in China (IV) (NCT06609187)
- 30 Oct 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT06609187)